Robert C Koski Form 4 ORAGENICS / BEVERLY KOSKI ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

KOSKI FAMILY LP

(Last) (First) (Middle)

3525 TURTLE CREEK BOULEVARD, UNIT 19-B

(Street)

DALLAS TX 75219

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ORAGENICS INC [ OGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/08/2017

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								12,864,822	D(1)(2)
Common Stock								1,572,523	D(3)
Common Stock								1,087,878	D(4)(8)
Common Stock								519,666	D(5)
Common Stock								20,000	I(6)	By Koski Management, Inc.
Common Stock								530,851	I(7)	By Trusts

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Convertible Preferred Stock	$0.25	11/08/2017		J		1,500,000(8)		(8)	(8)	Common Stock	3,000,000	$0.00	3,000,000	D
Common Stock Warrant	$0.31	11/08/2017		J		2,419,355(9)		05/08/2018	11/08/2024	Common Stock	2,419,355	$0.31	5,419,355	D

1. Name and Address of Reporting Person^*

KOSKI FAMILY LP

(Last) (First) (Middle)

3525 TURTLE CREEK BOULEVARD, UNIT 19-B

(Street)

DALLAS TX 75219

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

KOSKI ROBERT C

(Last) (First) (Middle)

7362 HAWKINS ROAD

(Street)

SARASOTA FL 34241

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

KOSKI THOMAS L

(Last) (First) (Middle)

4995 ASHLEY PARKWAY

(Street)

SARASOTA FL 34241

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

KOSKI CHRISTINE L

(Last) (First) (Middle)

3525 TURTLE CREEK BOULDEVARD, UNIT 19-B

(Street)

DALLAS TX 75219

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

KOSKI BEVERLY

(Last) (First) (Middle)

3525 TURTLE CREEK BOULDEVARD, UNIT 19-B

(Street)

DALLAS TX 75219

(City) (State) (Zip)

Explanation of Responses:

1. Shares owned directly by Koski Family Limited Partnership ("KFLP"). Shares owned indirectly by the KFLP general partners: Koski Management, Inc. (solely owned by Beverly Koski), Christine L. Koski, Robert C. Koski and Thomas L. Koski, each of whom is a general partner of the partnership or the controlling person of a corporate general partner of the partnership.

2. Each reporting person disclaims beneficial ownership of all indirectly owned securities in excess of such reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner for purposes of Section 16 or any other purpose.

3. Shares owned directly by Christine L. Koski.

4. Shares owned directly by Robert C. Koski, a director of the Company.

5. Shares owned directly by Thomas L. Koski.

6. Shares owned indirectly by Beverly Koski (through Koski Management, Inc.).

7. Shares owned by trusts of which Mr. Robert C. Koski is sole trustee. Such trusts are as follows: the Robert Clayton Koski Trust for the benefit of Anthony James Hunter (100,000 shares); the Robert Clayton Koski Trust for the benefit of Hunter Buchanan Koski (100,000 shares); the Robert Clayton Koski Trust for the benefit of Clayton Ward Bennett (100,000 shares); the Robert Clayton Koski Trust for the benefit of Robert Edward Koski (100,000 shares); and the Robert Clayton Koski Trust for the benefit of Elyse Margaux Koski (97,666 shares). Mr. Koski disclaims beneficial ownership of the shares held by the trusts except to the extent of any pecuniary interest.

8. On November 8, 2017 the Company issued to the KFLP 1,500,000 shares of Series B Preferred Stock at a purchase price of $0.50 per share which are convertible into 3,000,000 shares of the Company's Common Stock, based on a conversion ratio of one share of Series B Preferred Stock into two shares of common stock. The purchase price per share represented by the shares of common stock the Series B Preferred Stock is convertible into equates to $0.25 per share. The Series B Convertible Preferred Stock will be convertible into shares of common stock commencing on the effective date of shareholder approval and has no expiration date.

9. On November 8, 2017, the Company issued to the KFLP in the private placement a warrant to purchase 2,419,355 shares of Common Stock. The Warrant has a term of seven years from the date of issuance, are non-exercisable until 6 months after issuance, and have an exercise price of $0.31 per share. The exercisability of the Warrant into shares of common stock is also subject to shareholder approval.

Remarks:

	/s/ Mark A. Catchur, as Attorney-in-Fact for CHRISTINE L. KOSKI, BEVERLY KOSKI, KOSKI FAMILY LIMITED PARTNERSHIP, ROBERT C. KOSKI AND THOMAS L. KOSKI	11/13/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.